INTRODUCTION {#S5}
============

The central dopaminergic system has been implicated in the modulation of emotional behavior, the pathophysiology of depression, and the mechanisms of antidepressant drugs, by clinical and preclinical evidence([@R23]; [@R65]; [@R66]). In experimental animals the dopaminergic projections from the ventral tegmental area (VTA) to the nucleus accumbens shell and medial prefrontal cortex (PFC) were shown to play major roles in learning associations between operant behaviors or sensory stimuli and reward, and in mediating the reinforcing properties of drugs of abuse and natural rewards([@R92]; [@R74]). These observations lead to the hypothesis that reduced mesocorticolimbic DA function underlies the anhedonia, amotivation and psychomotor slowing associated with major depression([@R82]; [@R31]; [@R65]).

A variety of experimental data support this hypothesis. Reductions in dopaminergic function associated with alpha-methyl-para-tyrosine administration can induce depressive symptoms in susceptible individuals([@R9]; [@R41]). Conversely, dopamine receptor agonists (e.g., pramipexole) exert antidepressant effects in placebo-controlled studies([@R91]; [@R96]). In MDD-subjects DA turnover appears abnormally decreased, as concentrations of the DA metabolite, homovanillic acid(HVA), consistently are reduced in the cerebrospinal fluid(CSF) and jugular vein plasma *in vivo*([@R55]; [@R91])\--particularly in depressives who manifest psychomotor retardation or melancholic features([@R7]) and in the caudate and accumbens *post mortem* in suicide victims([@R8]). Neuroimaging studies of MDD showed reduced \[^11^C\]*L*-DOPA uptake across the blood-brain-barrier([@R2]) and increased striatal binding to D~2~/D~3~-receptor radioligands that were sensitive to endogenous DA concentrations, although these latter findings were limited to cases who showed psychomotor slowing([@R25]; [@R21]). In such cases the elevated D~2~/D~3~-receptor binding may have reflected either reduced intrasynaptic DA concentrations, or compensatory up-regulation of D~2~/D~3~-receptor density or affinity([@R84]; [@R56]). Nevertheless, studies whose samples were not predominantly composed of psychomotor slowed cases found no difference in D~2/3~-receptor levels during depression([@R51]; [@R69]; [@R63]; [@R42]). Similarly, some([@R61]) but not other([@R10]; [@R5]; [@R95]) studies of striatal DA transporter(DAT) binding reported reduced availability in MDD-subjects versus controls.

The specific DA receptor subtypes that mediate dopaminergic function in reward processing, emotional behavior and depression remain incompletely understood, partly due to the paucity of highly selective agonists and antagonists. In mice phenotypic analysis of DA receptor knockouts identified roles for the D~1~, D~2~ and D~3~ receptor subtypes in mediating dopamine's effects on reward processing and/or emotional behavior. A complex role for D~1~-receptors in particular was supported by both preclinical and clinical evidence. In genetically-engineered mice deletion of the D~1~-receptor attenuated the reinforcing properties of rewarding stimuli \[reviewed in([@R43])\]. Nevertheless, the euphoric effects of cocaine appeared blunted by D~1~-receptor-like antagonist administration in cocaine addicts([@R72]; [@R87]; [@R43]). Moreover, in rats the reduction in sucrose consumption resulting from chronic mild stress, a purported model of anhedonia, was associated with increased D~1~-receptor density in the caudate-putamen(but not the accumbens or amygdala)([@R68]), and in humans with schizophrenia, D~1~-receptor antagonists alleviated "negative" symptoms such as anhedonia and amotivation([@R18]; [@R48]).

With respect to other emotional states, in rats intra-amygdaloid injection of D~1~-receptor antagonists exerted anxiolytic effects([@R17]) and impaired retention of inhibitory avoidance learning(fear-based memory)([@R54]). Moreover, D~1~-receptor knockout mice showed deficits in fear extinction and reversal learning (putative correlates of resilience to stress or adaptation to behavioral reinforcement, respectively), and abnormal long-term potentiation of synapses on PFC neurons([@R28]; [@R29]; [@R44]). These data appeared consistent with evidence that an optimal range of D~1~-receptor stimulation is required to facilitate working memory, as intracortical administration of either agonists or antagonists for D~1~-receptors impairs working memory performance in rodents and primates([@R6]; [@R89]; [@R37]; [@R71]).

In MDD the D~1~-receptor has been assessed by genetic, *post-mortem* and neuroimaging studies. Although polymorphisms in the human D~1~-receptor gene have not been associated specifically with the vulnerability for developing MDD([@R52]), one study([@R75])(but not another([@R49])) found an association with bipolar disorder (BD). *Post-mortem* studies of D~1~-receptor binding found no difference in the striatum([@R8]) or right amygdala([@R50]) in MDD-subjects who were *unmedicated* at the time of death (n=28 and 11, respectively) versus controls, although one of these found increased D~1~-receptor density and reduced affinity in the accumbens in *medicated* suicide victims([@R8]). Finally, a PET-\[^11^C\]SCH-23390 study reported reduced D~1~-receptor binding in the striatum bilaterally in 10 depressed MDD-subjects with anger attacks([@R19]). It remained unclear whether this finding would generalize to other MDD subtypes. In subjects with BD(n=10), a PET-\[^11^C\]SCH-23390 study reported no difference in striatal D~1~-receptor binding relative to controls, although only three of the subjects were depressed([@R80]). The latter study also reported reduced binding in the frontal cortex of BD-subjects, but because \~one-quarter of \[^11^C\]SCH-23390 binding in the frontal cortex is attributable to 5-HT~2A~ receptor binding, this difference remained difficult to interpret([@R26]).

The recent development of a PET radioligand using (+)-5-(7-Benzofuranyl)-8-chloro-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (NNC-112), a potent and selective D~1~-receptor antagonist, provided sufficiently high specific-to-nonspecific binding ratios to permit meaningful assessment of D~1~-receptor binding in both extrastriatal and striatal tissues([@R3]; [@R39]). The current study is the first application of \[~11~C\]NNC-112 in investigations of D~1~-receptor binding in mood disorders, and the first *in vivo* study of D~1~-receptor binding in depressed subjects selected more generally according to the criteria for MDD. We hypothesized that the mean D~1~-receptor BP~ND~ would be reduced in the striatum of MDD-subjects versus controls, based on the data reported in MDD-subjects with anger attacks([@R19]). In addition, we sought to more specifically localize D~1~-receptor binding abnormalities in MDD using an MRI-based technique previously developed for characterizing the dopaminergic system in striatal subregions([@R23], [@R22]).

PATIENTS AND METHODS {#S6}
====================

Participants {#S7}
------------

Right-handed volunteers 18 to 55 years of age, who either met DSM-IV criteria for recurrent or chronic MDD in a current major depressive episode(n=18), or had no personal history of a major psychiatric disorder(n=19) were studied([Table 1](#T1){ref-type="table"}). Diagnosis was established by an unstructured interview with a psychiatrist and the Structured Clinical Interview for DSM-IV([@R4]). Exclusion criteria for all subjects included a history of psychosis, exposure to psychotropic drugs, cigarette smoking or any medication likely to affect cerebral function within the three weeks prior to scanning(eight for fluoxetine), major medical or neurological illnesses, lifetime history of substance-dependence, substance-abuse within one year, recent suicidal behavior or serious suicidal ideation, current pregnancy, peri- or post-menopause status. Depressed subjects with secondary anxiety disorders were not excluded. Additional exclusion criteria for the controls included having a first-degree relative with a mood, anxiety or psychotic disorder. Subjects provided written informed consent as approved by the NIMH IRB.

Data Acquisition and Processing {#S8}
-------------------------------

The severity of depressive symptoms was rated using the Montgomery-Asberg Depression Rating Scale(MADRS)([@R64]) and the Inventory of Depressive Symptoms-Clinician Version(IDS-C). Anxiety symptoms were rated using the Hamilton Anxiety Rating Scale(HAM-A([@R40])), and anhedonia was assessed using the anhedonia subscale of the IDS-C. Psychomotor speed was assessed using the reaction time measured during performance of the Rapid Visual Information Processing (RVIP) task from the Cambridge Neuropsychological Test Automated Battery(CANTAB; Cambridge Cognition Ltd, Cambridge, UK). These computerized tasks were presented on an Advantech computer(Model PP-120T-RT) with a 10 1/2 inch touch-screen monitor.

PET scans were acquired using a GE-Advance scanner in 3D-mode(reconstructed 3D spatial-resolution=6 mm full-width at half-maximum\[FWHM\]). The PET data were reconstructed using a Hanning-filter and Gaussian fit scatter correction method. An 8-minute transmission scan was acquired using rotating rods of ^68^Ge/^68^Ga, and used to perform measured attenuation correction of the emission image. \[^11^C\]NNC-112 was synthesized as described previously([@R39]). Following intravenous bolus administration of a mean injected dose=19.5±1.24 mCi (range 15.5--20.8) of high specific activity \[^11^C\]NNC-112, a 90-minute dynamic emission scan was acquired as 27 frames of increasing length(number × frame duration \[min\]:6×0.50; 3×1.0; 2×2.0; 16×5.0).

Head motion was minimized during scanning by stabilizing each subject's head position a thermoplastic mask fixed to the scanner table. In addition, the PET data were corrected for head motion by aligning all frames to a mean image of frames 3 through 8, using AIR([@R93]) as implemented in Medx(Sensor Systems Inc., Sterling, VA). To provide an anatomical framework for the PET analysis, MRI scans were acquired using a GE 1.5 or 3.0T scanner and T~1~-weighted pulse sequence optimized to enhance tissue-contrast resolution(voxel size=0.86×0.86×1.2 mm). The realigned PET frames were coregistered to the anatomical MRI for each subject using fMRIB\'s Linear Image Registration Tool and a mutual information cost-function([@R47]).

Data Analysis {#S9}
-------------

The D~1~-receptor binding parameter estimations were performed voxel-wise using a multilinear reference-tissue model(MRTM) using a receptor-free reference-region(cerebellum) without arterial data. The BP~ND~ values thus obtained were proportional to the receptor density(*B*~max~) and independent of blood flow(K~1~)([@R45]). The value of *k′~2~* was estimated by the 3-parameter MRTM using regions-of-interest(ROI) time-activity curves for the striatum. The *R*~1~ images, which reflect relative blood flow, were used for image co-registration with MRI. The generation of parametric BP~ND~ images from the dynamic \[^11^C\]NNC-112 PET data was performed in PMOD 2.5([@R62]).

Hypothesis testing was performed in 5 striatal ROI defined over the anteroventral striatum(AVS; accumbens area, ventromedial caudate, anteroventral putamen), dorsal caudate(DC), middle caudate(MC), ventral putamen(VP), dorsal putamen(DP), as described previously([@R8]; [@R22]). Based on evidence that DA release during reward processing is lateralized in healthy humans([@R59]; [@R85]), hemisphere was included as a factor in the analyses. To allow comparison with previously reported negative findings from *post-mortem* studies of depression([@R50]), we examined binding in the amygdala *post hoc*.

Additional *exploratory* analyses were conducted *post hoc* in cortical regions known to contain moderately-high D~1~-receptor concentrations and to be implicated in the mesocorticolimbic dopaminergic system and the pathophysiology of MDD([@R90]): right and left insula/lateral orbitofrontal cortex(i.e., sulcal BA47)([@R67]) and anterior cingulate cortex(ACC; including subgenual and pregenual areas). Amygdala, insular and ACC ROI were defined as described in([@R12]).

The reference-region was defined in the cerebellar cortex, with the ROI situated at least one FWHM ventral to the occipital and temporal cortices, and away from the cerebellar vermis and brain edge.

Statistical Analysis {#S10}
--------------------

The mean BP~ND~ for each ROI was compared between groups using a linear mixed-model and the heterogeneous compound-symmetry covariance-matrix performed using SPSS. For ROI where the model indicated significant group effects, *post-hoc* comparisons of BP~ND~ across groups were performed using unpaired t-tests. In regions where group effects were detected the relationship between D~1~-receptor BP~ND~ and clinical ratings of depression, anxiety and anhedonia were assessed *post hoc* by computing Spearman's bivariate correlation coefficients(rho, ρ).

RESULTS {#S11}
=======

The groups did not differ significantly for mean age or gender composition([Table 1](#T1){ref-type="table"}). Mean depression, anxiety and anhedonia ratings were greater(p\<0.001, T=−4 to −17) in MDD-subjects than controls([Table 1](#T1){ref-type="table"}). Reaction times on the RVIP did not differ significantly between the MDD and control groups(t=−1.50, p=0.15). Performance measured by the number of omission (HC 4.5±2.7, MDD 6.9±5.5, t=−1.64, p=0.12) or commission errors (HC 0.33±1.29, MDD 1.35±1.83, T= −1.794, p=.083) on the RVIP also did not differ significantly between groups. Five MDD-subjects had comorbid anxiety disorders\[generalized social phobia(n=4), specific phobia(n=1)\]. Two MDD-subjects had a remote history of alcohol abuse and one a remote history of marijuana abuse.

The rank order of the \[^11^C\]NNC BP~ND~ values was caudate, putamen\>AVS\>amygdala\>insula \> ACC \>cerebellum([Table 2](#T2){ref-type="table"}), consistent with the relative D~1~-receptor densities measured *post-mortem* in humans([@R14]).

The mean D~1~-receptor BP~ND~ was 14% lower in the left MC of the MDD-subjects versus controls(T=2.21, p=0.03, [Figure 1](#F1){ref-type="fig"}, [Figure 2](#F2){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). The magnitude of this difference was similar after removing the 3 subjects with a remote history of substance abuse (12.6%), the 7 previously-medicated MDD-subjects(13.5%) or the 5 subjects with co-morbid phobias(11%). In the remaining ROIs mean D~1~-receptor BP~ND~ did not differ between the control and MDD groups([Table 2](#T2){ref-type="table"}).

In *post-hoc* assessments, a main effect of hemisphere was evident in several regions ([Figure 1](#F1){ref-type="fig"}, [Figure 3](#F3){ref-type="fig"}), including AVS(F=87.8, p=8.01e^−11^), VP(F=8.84, p=3.10e^−2^), DP(F=25.5, p=1.56e^−5^), MC(F=308, p=1.09e^−5^) and DC(F=98.5, p=1.77e^−4^). A group-by-gender-by-hemisphere interaction(F=7.33, p=0.011) was detected in the DP, which was accounted for by a greater interhemispheric difference in BP~ND~ in female controls versus female MDD-subjects([Figure 6](#F6){ref-type="fig"}). This interaction remained significant after including age as a covariate, or after removing from analysis the subjects who had a remote history of substance abuse(F=4.44, p=0.044), previous psychotropic medication exposure(F=6.17, p=0.020) or co-morbid phobia(F=5.83, p=0.023).

Age correlated with BP~ND~ in the left VP(ρ=−0.34, p=0.04), left DP(ρ=−0.33, p=0.04), right MC(ρ=−0.38, p=0.02), bilateral DC(left: ρ =−0.39, p=0.02; right: ρ =−0.38 p=0.02) and left insula(ρ =−0.42, p=0.01). The relationship between BP~ND~ and age showed a trend toward significance in right VP(ρ=−0.32, p=0.06), left MC(ρ=−0.29, p=0.08) and left insula(ρ=−0.32, p=0.052) but did not approach significance(p\>.10) in the right DP, AVS, ACC, or amygdala. Analyses were covaried for age where relevant.

A main effect of gender on BP~ND~ was significant in the AVS(F=4.21, p=0.048), VP(F=7.28, p=0.043), MC(F=9.72, p=0.026), and DC(F=9.77, p=0.026) but not in the DP(F=1.38, p=0.249). There were no significant group-by-gender interaction in any region(p\>0.1).

Exploratory, *post hoc* clinical correlations showed that BP~ND~ values in the left MC correlated inversely with illness duration(r= −0.53, p=0.02; [Figure 4](#F4){ref-type="fig"}), but did not correlate significantly with depression(MADRS), anxiety(HAM-A) or anhedonia(IDS-C anhedonia subscale) severity(i.e., p\>0.05). Reaction times on the RVIP correlated negatively with D~1~-receptor binding in the left MC in controls(r=−0.453, p=0.007) but not MDD-subjects(r= −0.096, p=0.358). The ratio of left-to-right BP~ND~ values in the MC correlated inversely with IDS-C anhedonia subscale ratings(r=−0.65, p=0.0040) but not with depression or anxiety ratings(p\>0.4). MDD-subjects with comorbid phobias did not differ in D~1~-receptor BP~ND~ in the left MC than non-phobic depressives.

Depression severity correlated negatively with BP~ND~ in right DP(MADRS ρ=−0.61, p=0.007, [Figure 6](#F6){ref-type="fig"}). Anxiety severity(HAM-A) correlated negatively with BP~ND~ in right DP(ρ=−0.48, p=0.045). Anhedonia ratings, age-at-onset, and illness-duration did not correlate significantly with BP~ND~ in the DP(p\>.05). In right DP, MDD-subjects with comorbid phobias showed lower D~1~-receptor BP~ND~ than non-phobic depressives(Z=−2.3, p=0.019).

Mean BP~ND~ values for depressed subjects who previously were exposed to psychotropic medications(n=7) showed no significant difference versus drug-naive subjects(n=11) in any region(p\>.10).

DISCUSSION {#S12}
==========

The mean D~1~-receptor binding was 14% lower in the left MC of MDD-subjects versus healthy controls([Figure 1](#F1){ref-type="fig"}). Moreover, while significant differences in D~1~-receptor binding between the right and left hemispheres existed in controls, this normal asymmetry was absent in the DP in depressed females([Figure 6](#F6){ref-type="fig"}). *Post-hoc* assessments in the MDD-sample showed that D~1~-receptor binding in the left MC correlated inversely with illness duration and anhedonia ratings. In addition, the left MC D~1~-receptor binding correlated inversely with psychomotor speed in the controls but not the depressives.

The abnormalities in striatal BP~ND~ in MDD likely reflect alterations in D~1~-receptor density and/or affinity for \[^11^C\]NNC-112. Although \[~11~C\]NNC-112 binding is reversible *in vivo*([@R1]), it is insensitive to displacement by endogenous dopamine([@R13]). Among DA receptors NNC-112 is highly selective for D~1~-receptors(e.g., the D~1~:D~2~ receptor binding ratio=4500)([@R27]). The major limitation in specificity is that \[^11^C\]NNC-112 is only 2--3-fold more selective for D~1~-receptors than 5-HT~2A~ receptors([@R27]). Thus in the frontal cortex, where the 5-HT~2A~ receptor and D~1~-receptor concentrations are comparable, up to 25% of \[~11~C\]NNC-112 binding is attributable to 5-HT~2A~-receptor binding([@R26]; [@R78]). In the striatum, however, where the ratio of D~1~:5-HT~2A~ receptor density is relatively higher, the 5-HT~2A~ contribution to the measured BP~ND~ is negligible([@R78]). Thus, the abnormalities observed in the MC and DP in MDD most likely reflect differences in D~1~-receptor binding.

The mean 14% decrement in D~1~-receptor BP~ND~ in the left MC in our MDD-subjects appeared consistent with the 13% reduction in binding in the left striatum reported by Dougherty et al (2002) in MDD-subjects with anger attacks. Our data extended this previous finding by showing that the left striatal D~1~-receptor binding also was decreased in a depressed sample selected more generally according to MDD criteria. We did not observe any abnormality in the right striatum, however, raising the possibility that a deficit in right striatal D~1~-receptor binding may be specific to MDD-subjects with anger attacks.

Our data more specifically localized the abnormality in left striatal D~1~-receptor binding in MDD to the left MC, which showed the greatest magnitude-of-difference and effect-size across the striatal ROI([figure 1](#F1){ref-type="fig"}, [figure 3](#F3){ref-type="fig"}). Because of the proximity of the MC to other striatal ROI, measured signals from the MC were weakly influenced by those from the AVS and DC which were partly continuous with the MC([@R23], [@R22]). Since parts of these ROI were separated by less than the 6 mm resolution of our PET measures, demonstrating differential regional abnormalities in MDD depended upon showing that the mean difference in BP~ND~ was greater in the MC than in the DCA or AVS. This approach was facilitated by the low \[~11~C\]NNC-112 specific binding in extrastriatal areas, which reduced the number of comparisons required across adjacent regions. The ability to assess relative differences in radiotracer concentration across conditions in ROI separated by less than the FWHM resolution is central to PET's utility in localizing voxels of maximal difference in brain mapping studies(Fox et al. 1986; Friston et al. 1996). Because of these spatial resolution limitations, however, the non-significant trends seen in the left AVS and left DC([figure 1](#F1){ref-type="fig"}) are difficult to interpret since they may reflect spilling in of radioactivity from the MC([@R57]).

The MC region is the major striatal target of *predominantly ipsilateral*, afferent projections from the ACC and orbitofrontal cortex(OFC)([@R30]; [@R38]). Since the grey matter volume and/or neuronal counts in these cortical areas is reduced in MDD([@R24]), the regional specificity of the reduction in D~1~-receptor binding to the MC raises the possibility that this abnormality reflects a reduction in afferent neuronal terminals from the cortex, and thus in the density of synapses where D~1~-receptors are expressed post-synaptically. This hypothesis appears compatible with findings that in MDD both the reduction in D~1~-receptor binding in the MC([figure 1](#F1){ref-type="fig"}) and the reduction in grey matter volume in the ACC and OFC are predominantly left-lateralized([@R24]). This hypothesis may also be compatible with the finding that the D~1~-receptor binding in the left MC correlated inversely with illness duration([figure 4](#F4){ref-type="fig"}), since the reductions in ACC volume reportedly worsen across time in mood disorders([@R53]). In contrast, perturbations in D~1~-receptor binding in MDD may be less likely to reflect local changes in receptor expression associated with changes in DA release, as the severe DA deficiency state accompanying Parkinson's Disease is not associated with changes in D~1~-receptor binding or density([@R70]; [@R76]). Moreover, while changes in D~1~-receptor regulation at the level of G-protein coupling may exist in the DA depleted striatum([@R32]), such a change would not likely be evinced by corresponding changes in D~1~-receptor antagonist binding to PET radioligands([@R70]; [@R76]) which typically bind to receptors in high versus low affinity states with comparable potency.

*Post-hoc* analyses revealed an altered interhemispheric ratio of D~1~-receptor BP~ND~ that differed significantly between depressed and control females in the DP. Specifically, the depressed females showed a loss of the asymmetry in D~1~-receptor binding that was evident in the controls([Figure 6](#F6){ref-type="fig"}). This difference was explained by D~1~-receptor BP~ND~ values that were non-significantly lower in the left DP and non-significantly higher in the right DP in depressed females versus control females([figure 6](#F6){ref-type="fig"}).

In other striatal regions the D~1~-receptor binding also showed highly significant laterality effects in healthy controls, which did not differ significantly between groups. In the caudate and AVS(accumbens area), the BP~ND~ was lower in the left hemisphere than the right. In contrast, in the putamen the direction of the laterality effect was reversed(left \>right). This difference between caudate and putamen may explain the absence of laterality effects in striatal \[~11~C\]SCH-23390 binding in([@R19]), who combined caudate and putamen into a single ROI. Other studies employing neuroimaging or autoradiographic techniques to assess D~1~-receptor binding in depressed or healthy humans([@R15]; [@R79]; [@R80]; [@R8]) or experimental animals([@R14]; [@R11]) did not examine laterality effects.

Asymmetrical D~1~-receptor binding across hemispheres is consistent with several reports of lateralized function within the dopaminergic system. The amount of DA release in human striatal subregions in response to unpredicted reward([@R59]), DA release in the rodent caudate during voluntary behavior([@R94]), and preference for self-stimulation induced by localized amphetamine administration in rats all show prominent laterality effects([@R35]; [@R36]). In healthy humans greater D~2~-receptor availability in the left relative to the right striatum was associated with greater positive incentive motivation ([@R85]). In right-handed humans DA concentrations were higher in the left putamen than the right([@R34]; [@R16]), and in marmosets levels of DA and HVA were higher in the right caudate and putamen than the left([@R77]). Consistent with these data humans also showed higher dopamine transporter density in the left putamen and caudate versus the right, irrespective of handedness([@R86]). \[Although the lateralization of motor dominance("handedness") has been associated with variation in elements of the dopaminergic system including COMT([@R73]), it remains unclear whether handedness also would influence D~1~-receptor BP~ND~.\] Finally, our finding that the loss of normal asymmetry in D~1~-receptor BP~ND~ in MDD appeared specific to females was notable given evidence that the direction of asymmetry preference for self-stimulation in rats showed prominent sex-effects([@R33]).

Since the mesocorticolimbic dopaminergic system plays major roles in the neural processing of reward and motivation, it is conceivable that either a deficit in dopaminergic function in the left MC, or alterations in the interhemispheric ratio of D~1~-receptors that may result from such a deficit, may disrupt the normally lateralized function of this system and thereby contribute to the depressed mood, anhedonia and amotivation associated with MDD([@R65]; [@R58]). Compatible with this hypothesis, the ratio of left-to-right D~1~-receptor binding in the MC correlated inversely with the IDS-C anhedonia subscale(r=−0.65, p=0.0040). In the left MC functional abnormalities have been identified during reward processing in MDD. In independent samples of MDD-subjects the magnitude of DA release during unpredicted monetary reward and the hemodynamic response to anticipated monetary reward were abnormally blunted specifically in the left MC([@R20]).

The relationship between the response latencies on a sustained attention task (RVIP) and D~1~-receptor binding in the left MC in healthy controls suggests that the abnormal D~1~-binding group in MDD also may play a role in the psychomotor or cognitive impairment associated with MDD. The mean response latency was 12% slower in depressives than controls, as expected([@R83]), although we were underpowered to establish the statistical significance of this difference. Although reaction times measured on the RVIP reflect both psychomotor speed and sustained attention, these variables generally are confounded on neuropsychological assessments of psychomotor speed. In controls the response latencies correlated inversely with BP~ND~ in the left MC (explaining 20.5% of the variance) implying the reduction in D~1~-receptor binding in this region in MDD may contribute to the psychomotor slowing associated with depression. The absence of a normal correlation between reaction time and MC-BP~ND~ in the MDD group also may be compatible with this hypothesis. Notably, psychomotor slowing previously was associated with reduced dopaminergic function in the left caudate in MDD, as ([@R60]) reported that \[^18^F\]DOPA was reduced specifically in the left caudate in MDD patients with psychomotor retardation compared to both healthy controls and MDD patients without psychomotor slowing.

The inverse correlation between D~1~-receptor binding and age is consistent with the results of previous PET([@R79]; [@R46]; [@R88]) or autoradiography studies([@R50]) conducted in humans or experimental animals([@R81]). In humans [@R88] reported a 6--7% decline in \[^11^C\]SCH-23390 binding to D~1~-receptors per decade in the caudate and putamen, comparable to the 3--6% decline in the BP~ND~ for \[~11~C\]NNC-112 per decade detected herein (assessed relative to the y-intercept for predicted value at birth; [figure 5](#F5){ref-type="fig"}). In contrast, the relationship between BP~ND~ and age was not significant in the amygdala, consistent with the data of [@R50] who observed no significant age effect on D~1~-receptor density measured *post mortem* in the human amygdala.

A limitation of our study was that we modeled the BP~ND~ for \[^11^C\]NNC-112 using a simplified reference tissue model to avoid arterial cannulation. This approach used the time-tissue radioactivity concentration in a reference region, the cerebellum, to estimate the concentration of free plus non-specifically bound radiotracer in all regions. However, without arterial plasma we were unable to measure the distribution volume of \[^11^C\]NNC-112 in the cerebellum. Consequently, a difference in BP~ND~ between groups could have been accounted for by abnormal \[^11^C\]NNC-112 binding either in the region-of-interest or the reference tissue. However, an abnormality of tracer uptake in the reference tissue could not account for the regionally specific group difference or the group-by-gender-by-hemisphere interaction found in the left MC and the DP, respectively.

In conclusion, reduced D~1~-receptor binding in the left MC, and in females an altered symmetry in D~1~-receptor binding in the DP, may contribute to dysfunction within the central dopaminergic system during depression. The prominent laterality effects we observed for striatal D~1~-receptor binding converges with other evidence indicating that DA concentrations are lateralized within the striatum([@R34]; [@R16]; [@R77]), and that the function of the central dopaminergic system in the striatum is lateralized during reward processing([@R59]), voluntary movement([@R94]) and self-stimulation behavior([@R35]; [@R36]; [@R33]). Since dopaminergic projections into the striatum modulate the neural processing of reward learning, motivated behavior and psychomotor activity, alterations in the interhemispheric ratio of D~1~-receptor binding conceivably may disrupt the normally lateralized function of this system, and thereby contribute to the depressed mood, psychomotor slowing, anhedonia and amotivation that characterize depression.
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![Dopamine-D~1~ receptor binding potential in healthy control and MDD groups in the left and right hemispheres for the striatal regions-of-interest\
\*p\<0.05: D~1~-receptor binding was significantly lower in the left middle caudate (MC) in the MDD group relative to control group.\
\*\*p\<0.05, \*\*\*p\<0.001: The main effect of hemisphere on BP~ND~ was significant in the anteroventral striatum (AVS), ventral putamen (VP), dorsal putamen (DP), middle caudate (MC), and dorsal caudate (DC) regions-of-interest](nihms69980f1){#F1}

![Representative parametric dopamine-D~1~ receptor BP~ND~ images through the striatum in a control subject (left panel) and an MDD subject (right panel)\
Within each panel the upper row of images show axial (left) and coronal (right) sections through the anatomical MRI, on which the regions-of-interest (ROI) were defined ([@R22]), and the lower row of images show parametric images of the non-displaceable component of the D~1~-recetor binding potential (BP~ND~) modeled from PET emission images. The MRI and PET images for each subject are co-registered. The axial images show the plane containing both the anterior and posterior commissures. The orthogonal lines locate approximately the center of the caudate head on this bi-commissural plane. The coronal sections pass through the anterior striatum, which at the level shown is composed predominantly of the caudate head. The middle caudate region is evident in the coronal sections, where it is situated immediately above the bicommissural plane (marked by the horizontal line). The D~1~-receptor BP~ND~ consistently was higher in the right caudate than the left in both groups (see [figure 1](#F1){ref-type="fig"}, [figure 3](#F3){ref-type="fig"}), as evinced in these representative images. The mean BP~ND~ value in the left middle caudate of the MDD group was lower than in the control group ([figure 1](#F1){ref-type="fig"}).](nihms69980f2){#F2}

![Dopamine-D~1~ receptor binding potential in the left and right hemispheres for each striatal region-of-interest showing the consistency of laterality effects. The left- and right-sided values corresponding to a single participant are connected by a line\
Main effects of hemisphere on regional binding potentials were significant in all five regions-of-interest (see [figure 1](#F1){ref-type="fig"} and [results](#S11){ref-type="sec"} section for significance levels).](nihms69980f3){#F3}

![Relationship between dopamine-D~1~ receptor binding potential in the left middle caudate and illness duration in the MDD sample\
The D~1~-receptor binding potential in the left middle caudate correlated inversely (r=−0.531, p=0.02) with illness duration (calculated as time since illness onset).](nihms69980f4){#F4}

![Relationships between age and D~1~-receptor BP~ND~ in the middle caudate and ventral putamen for all subjects\
Age correlated negatively with \[^11^C\]NNC-112 BP~ND~ in the middle caudate, ventral putamen, and most of other striatal regions examined (ρ=−0.33 to −0.42, p=0.01 to 0.04; see text).](nihms69980f5){#F5}

![Mean (+/− SEM) binding potential values for the right and left dorsal putamen separated by sex and diagnosis. In females with MDD the difference in D~1~-receptor BP~ND~ between the right and left hemispheres of the dorsal putamen was significantly less than that of the female controls\
In the dorsal putamen the group-by-gender-by-hemisphere interaction was significant (F=7.33, p=0.011). Abbreviations: HC, healthy control; MDD, major depressive disorder.](nihms69980f6){#F6}

###### 

Demographic and clinical characterization of the study samples.

                                                                 Control (n=19)   MDD (n=18)
  -------------------------------------------------------------- ---------------- --------------------
  **Proportion Female (n)**                                      58% (11)         61% (11)
  **Age (mean±SD)**                                              31 ± 8.5         31 ± 11
  **Proportion Right-Handed (n)**                                100% (19)        100% (18)
  **Depression Ratings**                                                          
    **MADRS (mean±SD)**                                          0.47 ± 1.2       22 ± 5.3
    **IDS-C (mean±SD)**                                          0.59 ± 1.3       27 ± 6.5
  **Anxiety Ratings**                                                             
    **HAMA (mean±SD)**                                           0.59 ± 1.2       12 ± 4.3
  **Anhedonia IDS_C Ratings (Mean ± SD)**                        0.06 ± 0.2       9.4 ± 3.2
  **Psychomotor Speed -- Response latency on RVIP**              437±78           491±118
  **Age-at-Illness-Onset (yrs) mean±SD (range)**                 N/A              19 ± 10 (6 -- 41)
  **Illness Duration (years) mean±SD (range)**                   N/A              12 ± 8.5 (2 -- 32)
  **Duration Medication-Free, Mos. mean±SD (range)**             N/A              23 ± 35 (4 -- 96)
  **Treatment Naïve (n)**                                        19               11
  **Subjects with Remote History of Suicide Attempts (n)**       0                4
  **Prior Exposure to Antipsychotic Agent (n)**                  0                1
  **Remote History of Alcohol (2) or Marijuana (1) Abuse (n)**   0                3
  **Comorbid Anxiety Disorder (n)**                              0                5

Abbreviations. MADRS, Montgomery Asberg Depression Rating Scale; HAM-A, Hamilton Rating Scale for Anxiety; IDS-C, Inventory of Depressive Symptoms-Clinician Rated; RVIP, Rapid Visual Information Processing

###### 

The mean and standard deviation of regional \[C-11\]NNC-112 binding potential values. The *a priori* hypothesis was tested in the striatal regions-of-interest (caudate, putamen). Analyses of D~1~-receptor binding in extrastriatal tissues were performed *post-hoc*.

  Region         Healthy Control   Major Depressive Disorder   Group Difference                         
  -------------- ----------------- --------------------------- ------------------ ------ ------ ------- ------------
  **VP**         right             2.41                        0.47               2.34   0.42   0.48    0.64
                 left              2.57                        0.51               2.40   0.40   1.15    0.26
                                                                                                        
  **DP**         right             2.49                        0.45               2.50   0.33   −0.11   0.92
                 left              2.66                        0.42               2.57   0.34   0.72    0.48
                                                                                                        
  **MC**         right             2.66                        0.53               2.59   0.41   0.47    0.64
                 **left**          2.07                        0.46               1.78   0.30   2.21    **0.03\***
                                                                                                        
  **DC**         right             2.77                        0.58               2.73   0.39   0.28    0.78
                 left              2.40                        0.45               2.19   0.46   1.39    0.17
                                                                                                        
  **AVS**        right             2.19                        0.47               2.09   0.37   0.73    0.47
                 left              1.86                        0.42               1.67   0.35   1.65    0.11
                                                                                                        
  **Amygdala**   right             1.64                        0.55               1.52   0.43   0.79    0.44
                 left              1.63                        0.76               1.47   0.43   0.88    0.39
                                                                                                        
  **Insula**     right             0.70                        0.13               0.69   0.14   −0.42   0.68
                 left              0.69                        0.12               0.68   0.16   −1.40   0.17
                                                                                                        
  **ACC**        bilateral         1.02                        0.23               1.03   0.23   −0.45   0.66

Abbreviations: ACC-anterior cingulate cortex; AVS-anteroventral striatum; DC-dorsal caudate; DP-dorsal putamen; MC-middle caudate; VP-ventral putamen
